Literature DB >> 23172883

Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.

Dana S Neel1, Trever G Bivona.   

Abstract

Non-small cell lung carcinoma (NSCLC) metastasis and drug resistance has been associated with epithelial-to-mesenchymal transition (EMT). This study reports the development of a robust gene expression signature of EMT in NSCLC and reveals new insights into the key molecular events that underlie EMT and drug resistance in NSCLC.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23172883      PMCID： PMC3537879          DOI： 10.1158/1078-0432.CCR-12-3232

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Genetic changes in squamous cell lung cancer: a review.

Authors:  Rebecca S Heist; Lecia V Sequist; Jeffrey A Engelman
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

Review 2.  EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.

Authors:  Jean-Charles Soria; Tony S Mok; Federico Cappuzzo; Pasi A Jänne
Journal:  Cancer Treat Rev       Date:  2011-11-25       Impact factor: 12.111

Review 3.  New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Juliann Chmielecki; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2011-07-20       Impact factor: 12.531

4.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

5.  An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Authors:  Lauren Averett Byers; Lixia Diao; Jing Wang; Pierre Saintigny; Luc Girard; Michael Peyton; Li Shen; Youhong Fan; Uma Giri; Praveen K Tumula; Monique B Nilsson; Jayanthi Gudikote; Hai Tran; Robert J G Cardnell; David J Bearss; Steven L Warner; Jason M Foulks; Steven B Kanner; Varsha Gandhi; Nancy Krett; Steven T Rosen; Edward S Kim; Roy S Herbst; George R Blumenschein; J Jack Lee; Scott M Lippman; K Kian Ang; Gordon B Mills; Waun K Hong; John N Weinstein; Ignacio I Wistuba; Kevin R Coombes; John D Minna; John V Heymach
Journal:  Clin Cancer Res       Date:  2012-10-22       Impact factor: 12.531

6.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors:  Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

7.  Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Authors:  Zhenfeng Zhang; Jae Cheol Lee; Luping Lin; Victor Olivas; Valerie Au; Thomas LaFramboise; Mohamed Abdel-Rahman; Xiaoqi Wang; Alan D Levine; Jin Kyung Rho; Yun Jung Choi; Chang-Min Choi; Sang-We Kim; Se Jin Jang; Young Soo Park; Woo Sung Kim; Dae Ho Lee; Jung-Shin Lee; Vincent A Miller; Maria Arcila; Marc Ladanyi; Philicia Moonsamy; Charles Sawyers; Titus J Boggon; Patrick C Ma; Carlota Costa; Miquel Taron; Rafael Rosell; Balazs Halmos; Trever G Bivona
Journal:  Nat Genet       Date:  2012-07-01       Impact factor: 38.330

8.  First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.

Authors:  Kim-Son H Nguyen; Joel W Neal
Journal:  Biologics       Date:  2012-09-25

9.  Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Authors:  Luping Lin; Trever G Bivona
Journal:  Chemother Res Pract       Date:  2012-08-29

10.  A systems view of epithelial-mesenchymal transition signaling states.

Authors:  Stuart Thomson; Filippo Petti; Izabela Sujka-Kwok; Peter Mercado; James Bean; Melissa Monaghan; Sean L Seymour; Gretchen M Argast; David M Epstein; John D Haley
Journal:  Clin Exp Metastasis       Date:  2010-12-31       Impact factor: 5.150
View more
  12 in total

1.  The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling.

Authors:  Wei Chen; Qiang Gao; Siqi Han; Fei Pan; Wei Fan
Journal:  Tumour Biol       Date:  2014-10-16

2.  ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.

Authors:  M R Yun; H M Choi; H N Kang; Yw Lee; H-S Joo; D H Kim; H R Kim; M H Hong; S O Yoon; B C Cho
Journal:  Oncogene       Date:  2017-09-25       Impact factor: 9.867

Review 3.  Role of miR-155 in drug resistance of breast cancer.

Authors:  Dan-dan Yu; Meng-meng Lv; Wei-xian Chen; Shan-liang Zhong; Xiao-hui Zhang; Lin Chen; Teng-fei Ma; Jin-hai Tang; Jian-hua Zhao
Journal:  Tumour Biol       Date:  2015-03-06

4.  Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.

Authors:  Linshui Zhou; Xin Lv; Junchao Yang; Yuanhong Zhu; Zhen Wang; Tingzhen Xu
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967

5.  MACC1 Is Associated With Epithelial-Mesenchymal Transition and Can Predict Poor Prognosis in Nasopharyngeal Carcinoma.

Authors:  Hao Cheng; Linxiang Zhou; Yalan Long; Juanjuan Xiang; Longhua Chen
Journal:  Front Oncol       Date:  2021-03-29       Impact factor: 6.244

Review 6.  Advances in targeted therapies and new promising targets in esophageal cancer.

Authors:  Abbes Belkhiri; Wael El-Rifai
Journal:  Oncotarget       Date:  2015-01-30

7.  Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.

Authors:  Nitu Bansal; Prasun J Mishra; Mark Stein; Robert S DiPaola; Joseph R Bertino
Journal:  Oncotarget       Date:  2015-06-20

8.  Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.

Authors:  Jie Yuan; Manran Liu; Li Yang; Gang Tu; Qing Zhu; Maoshan Chen; Hong Cheng; Haojun Luo; Weijie Fu; Zhenhua Li; Guanglun Yang
Journal:  Breast Cancer Res       Date:  2015-05-21       Impact factor: 6.466

9.  MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.

Authors:  Dario Presutti; Simonetta Santini; Beatrice Cardinali; Giuliana Papoff; Cristiana Lalli; Simone Samperna; Valentina Fustaino; Giuseppe Giannini; Giovina Ruberti
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

10.  Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways.

Authors:  M V Bais; G B Ozdener; G E Sonenshein; P C Trackman
Journal:  Oncogene       Date:  2014-06-02       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.